Efficacy and safety findings from a randomized phase III study of capecitabine (X) + oxaliplatin (O) (XELOX) vs. infusional 5- FU/LV + O (FOLFOX-6) for metastatic colorectal cancer (MCRC)
暂无分享,去创建一个
T. Conroy | M. Ychou | M. Ducreux | J. Douillard | M. Hebbar | A. Adenis | J. Bennouna | G. Lledo | R. Faroux | C. Rebischung